Frontlight ResearchEarly access
CompletedPhase 1
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PARALLEL AND PLACEBO-CONTROLLED SINGLE AND MULTIPLE ASCENDING DOSE TRIAL INVESTIGATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LIB-01 IN HEALTHY PARTICIPANTS
Key facts
- Who runs it
- Dicot AB
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 72 people enrolled
- Started
- 25 Aug 2023
- Ended
- 4 Apr 2024
- Type of study
- Interventional
- Record updated
- 5 October 2023
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 5 October 2023